Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO1 | P15559 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996029 | 0.83 | NQO1 (0.33) | NQO1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL21871901 | 0.78 | NQO1 (0.33) | NQO1CYP1A1CYP1A2CYP1B1CA1 | |
| SCHEMBL420547 | 0.76 | HSP90AA1 (0.32) | NQO1HPGDHSD17B10CYP1A1CYP1A2 | |
| SCHEMBL2817980 | 0.76 | NQO1 (0.32) | NQO1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL5658620 | 0.75 | ALDH1A1 (0.37) | NQO1ALDH1A1ALOX15HSD17B10CYP1A1 | |
| SCHEMBL21872197 | 0.75 | — | — | |
| SCHEMBL12731449 | 0.75 | CYP1A2 (0.33) | NQO1KDM4EALDH1A1MAPTALOX15 | |
| SCHEMBL27549881 | 0.73 | NQO1 (0.33) | NQO1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL8272925 | 0.73 | NQO1 (0.34) | NQO1ALDH1A1CYP1A1CYP1A2CYP1B1 | |
| SCHEMBL2737291 | 0.73 | NOTUM (0.32) | NQO1CA1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435742-B2 | Quinuclidine derivatives and pharmaceutical compositions containing the same | LABORATORIOS ALMIRALL S.A. (ES) | 2008-10-14 | — | — | US | claimed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | claimed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | claimed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | claimed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-16 | — | — | US | disclosed |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9770439-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-9518056-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-13 | — | — | US | disclosed |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MAYERS SQUIBB COMPANY (US) | 2016-07-14 | — | — | US | disclosed |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-06-09 | — | — | US | disclosed |
| WO-2006070192-A1 | THIAZOLE AND ISOTHIAZOLE DERIVATIVES THAT MODULATE THE ACIVITY OF CDK, GSK AND AURORA KYNASES | ASTEX THERAPEUTICS LIMITED (GB) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006056930-A2 | NOVEL 4 -AMINOPIPERIDINE DERIVATIVES AS PLASMEPSIN II INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-01 | — | — | WO | disclosed |
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | ALMIRALL, S.A. (ES) | 2006-05-04 | — | — | US | disclosed |
| WO-2006010452-A1 | PROCESS FOR PREPARING QUINUCLIDINIUM CARBAMATE DERIVATIVES | LABORATORIOS ALMIRALL, S.A. (ES) | 2006-02-02 | — | — | WO | disclosed |
| WO-2006003440-A1 | 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-01-12 | — | — | WO | disclosed |
| EP-1515968-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Almirall Prodesfarma AG (CH) | 2005-03-23 | — | — | EP | disclosed |
| WO-2005002552-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2005-01-13 | — | — | WO | disclosed |
| WO-2004000840-A2 | QUINUCLIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL PRODESFARMA AG (CH) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094751-A1 | Quinuclidine derivatives and pharmaceutical compositions containing the same | CHRM3, CHRM2, CHRM1 | NQO1 1223/4885KDM4E 1774/4885ALDH1A1 1793/4885 |
| US-20170362244-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | NQO1 3596/4885KDM4E 2069/4885ALDH1A1 1823/4885 |
| US-20170190708-A1 | PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT | TYMP, ZC3HAV1, TYMS | NQO1 3596/4885KDM4E 2069/4885ALDH1A1 1823/4885 |
| US-20160199355-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | NQO1 1868/4885KDM4E 3572/4885ALDH1A1 3966/4885 |
| US-20160158200-A1 | Combinations of Hepatitis C Virus Inhibitors | HAVCR2, EIF2AK2, MAVS | NQO1 1703/4885KDM4E 3714/4885ALDH1A1 3872/4885 |
| US-20200115357-A1 | LIVER X RECEPTORS (LXR) MODULATORS | NR1H2, NR1H3, NR1H4 | NQO1 1348/4885KDM4E 2079/4885ALDH1A1 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.